💊 Fármacos A-Z 🧬 Dianas 🛠 Herramientas 📚 Guías
Todos los fármacos Clases de fármacos Áreas terapéuticas Efectos Secundarios
Guías Glosario Línea de tiempo
Comparaciones Recorridos de fármacos Familias farmacológicas
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Tisotumab Vedotin

CHEMBL4297841 Phase 4 Aprobado Antibody drug conjugate
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Tisotumab vedotin is an antibody-drug conjugate (ADC) consisting of a human monoclonal antibody targeting tissue factor (TF/CD142), conjugated via a protease-cleavable linker to monomethyl auristatin E (MMAE), a microtubule-disrupting cytotoxin. Upon binding to TF-expressing tumor cells, the ADC is internalized and MMAE is released, inducing cell cycle arrest and apoptosis; TF-expressing tumor cells also receive direct antibody-mediated cytotoxicity. It is approved for recurrent or metastatic cervical cancer and is under investigation for bladder and non-small cell lung cancers.

Áreas terapéuticas

Ovarian Cancer Pancreatic Cancer Bladder Cancer Non-Small Cell Lung Cancer Prostate Cancer

Mecanismo de acción

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

Tisotumab vedotin is an antibody-drug conjugate (ADC) consisting of a human monoclonal antibody targeting tissue factor (TF/CD142), conjugated via a protease-cleavable linker to monomethyl auristatin E (MMAE), a microtubule-disrupting cytotoxin. Upon binding to TF-expressing tumor cells, the ADC is internalized and MMAE is released, inducing cell cycle arrest and apoptosis; TF-expressing tumor cells also receive direct antibody-mediated cytotoxicity. It is approved for recurrent or metastatic cervical cancer and is under investigation for bladder and non-small cell lung cancers.

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Yes, Tisotumab Vedotin is an approved drug. It has reached clinical phase 4. It is classified as a Antibody drug conjugate.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297841. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.